Twelve Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Adults

A Three-Stage, Modified-Blind, Dose-Escalating Study to Assess Efficacy and Safety of Resiquimod Gel for the Treatment of Common Warts in Adults

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00114920

Enrollment

Registered

2005-06-21

Start date

2004-03-31

Completion date

Unknown

Last updated

2007-02-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Warts

Keywords

Wart(s), Adults, Common Wart(s)

Brief summary

The primary purpose of this study is to evaluate the effectiveness in adults, of four different strengths of resiquimod gel applied to common wart(s) three times a week for twelve weeks. A second purpose is to evaluate the safety of the drug.

Interventions

DRUGResiquimod

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

SINGLE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Diagnosis of common warts * Two forms of birth control

Exclusion criteria

* Pregnant or breast feeding * Other types of wart(s), ie. plantar * Currently participating in another clinical study * Chronic viral hepatitis B or C

Design outcomes

Primary

Measure	Time frame
Clearance of treated common wart(s)	—

Secondary

Measure	Time frame
Partial clearance of treated common wart(s)	—
Wart recurrence	—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026